Dependent variables | MRSA – all (n = 59) | MSSA – all (n = 95) | P value | MRSA Survivors (n = 42) | MSSA Survivors (n = 61) | P value | MRSA nonsurvivors (n = 17) | MSSA nonsurvivors (n = 34) | P value |
---|---|---|---|---|---|---|---|---|---|
Total MV (days) | 8 (4–20) | 8 (3–14) | 0.02 | 12 (3–21) | 7 (3–10) | 0.006 | 5 (4–10) | 12 (6–15) | 0.28 |
VAP MV (days) | 6 (1–16) | 6 (1–10) | 0.04 | 9 (1–16) | 3 (1–9) | 0.03 | 3 (3–9) | 7 (4–12) | 0.38 |
Total inpatient LOS (days) | 20 (11–32) | 15 (11–23) | 0.04 | 21 (13–32) | 15 (10–25) | 0.06 | 12 (7–29) | 16 (13–20) | 0.27 |
VAP inpatient LOS (days) | 12 (7–23) | 13 (8–18) | 0.21 | 16 (9–26) | 13 (8–19) | 0.16 | 5 (3–12) | 13 (8–17) | 0.46 |
Total ICU (days)a | 13 (6–27) | 9 (6–16) | 0.006 | 15 (8–29) | 7 (4–12) | 0.0002 | 6 (5–12) | 13 (9–19) | 0.26 |
VAP ICU (days)a | 7 (3–16) | 7 (3–12) | 0.04 | 11 (7–20) | 6 (3–11) | 0.006 | 4 (3–10) | 10 (6–15) | 0.14 |
Total cost (US$) | 40,734 (18,347–71,064) | 36,523 (15,539–72,080) | 0.30 | 41,968 (24,173–74,249) | 34,939 (14,959–75,787) | 0.30 | 31,597 (17,820–62,967) | 45,854 (18,958–55,578) | 0.49 |